Shanghai Henlius Biotech (2696.HK) Privatization Update - These Are the Potential Risks Behind

599 Views12 Nov 2024 08:55
Investors are worried about whether the prospects for privatization will change. There're rumors Fosun Pharma may have encountered funding issues. Slow Pre-Condition approval process is also a concern
What is covered in the Full Insight:
  • Overview of 24Q3 Results
  • Fosun Pharma's Financial Health
  • Privatization Overview and Challenges
  • Potential Risks and Concerns
  • Future Outlook
Boomeranged on Mon, 25 Nov 2024 08:50
The Offeror has received the approval from NDRC and will continue to liaise with local authorities of MOC and prepare for the registration filing with SAFE. Despite some progress, the overall approval process for Pre-Conditions is still slower than expected. Due to Chinese New Year holiday, it's already good to complete Pre-Conditions in 25Q1. Investors are hardly entirely reassured by a long wait
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x